Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Danilo Galizia, Andrea Milani, Elena Geuna, Rossella Martinello, Celeste Cagnazzo, Manuela Foresto, Virginia Longo, Paola Berchialla, Gianfranca Solinas, Adele Calori, Bruna Grasso, Chiara Volpone, Gisella Bertola, Gisella Parola, Giancarla Tealdi, Piero Luigi Giuliano, Anna Maria Ballari, Massimo Aglietta, Filippo Montemurro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.

Original languageEnglish
Pages (from-to)4339-4344
Number of pages6
JournalCancer Medicine
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Diagnostic Self Evaluation
Adjuvant Chemotherapy
Prospective Studies
Breast Neoplasms
Terminology
Therapeutics
Incidence
Dysgeusia
National Cancer Institute (U.S.)
Paresthesia
Telemedicine
Anorexia
Constipation
Dyspnea
Nausea
Italy
Vomiting
Fatigue
Diarrhea
Surveys and Questionnaires

Keywords

  • adjuvant chemotherapy
  • breast cancer
  • chemotherapy-related side effects
  • common toxicity criteria for adverse events
  • duration
  • patient-reported outcomes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients : A prospective study. / Galizia, Danilo; Milani, Andrea; Geuna, Elena; Martinello, Rossella; Cagnazzo, Celeste; Foresto, Manuela; Longo, Virginia; Berchialla, Paola; Solinas, Gianfranca; Calori, Adele; Grasso, Bruna; Volpone, Chiara; Bertola, Gisella; Parola, Gisella; Tealdi, Giancarla; Giuliano, Piero Luigi; Ballari, Anna Maria; Aglietta, Massimo; Montemurro, Filippo.

In: Cancer Medicine, Vol. 7, No. 9, 01.09.2018, p. 4339-4344.

Research output: Contribution to journalArticle

Galizia, D, Milani, A, Geuna, E, Martinello, R, Cagnazzo, C, Foresto, M, Longo, V, Berchialla, P, Solinas, G, Calori, A, Grasso, B, Volpone, C, Bertola, G, Parola, G, Tealdi, G, Giuliano, PL, Ballari, AM, Aglietta, M & Montemurro, F 2018, 'Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study', Cancer Medicine, vol. 7, no. 9, pp. 4339-4344. https://doi.org/10.1002/cam4.1687
Galizia, Danilo ; Milani, Andrea ; Geuna, Elena ; Martinello, Rossella ; Cagnazzo, Celeste ; Foresto, Manuela ; Longo, Virginia ; Berchialla, Paola ; Solinas, Gianfranca ; Calori, Adele ; Grasso, Bruna ; Volpone, Chiara ; Bertola, Gisella ; Parola, Gisella ; Tealdi, Giancarla ; Giuliano, Piero Luigi ; Ballari, Anna Maria ; Aglietta, Massimo ; Montemurro, Filippo. / Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients : A prospective study. In: Cancer Medicine. 2018 ; Vol. 7, No. 9. pp. 4339-4344.
@article{f9ce1e7c3d83498f962d1ed4954b253e,
title = "Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study",
abstract = "Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.",
keywords = "adjuvant chemotherapy, breast cancer, chemotherapy-related side effects, common toxicity criteria for adverse events, duration, patient-reported outcomes",
author = "Danilo Galizia and Andrea Milani and Elena Geuna and Rossella Martinello and Celeste Cagnazzo and Manuela Foresto and Virginia Longo and Paola Berchialla and Gianfranca Solinas and Adele Calori and Bruna Grasso and Chiara Volpone and Gisella Bertola and Gisella Parola and Giancarla Tealdi and Giuliano, {Piero Luigi} and Ballari, {Anna Maria} and Massimo Aglietta and Filippo Montemurro",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/cam4.1687",
language = "English",
volume = "7",
pages = "4339--4344",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients

T2 - A prospective study

AU - Galizia, Danilo

AU - Milani, Andrea

AU - Geuna, Elena

AU - Martinello, Rossella

AU - Cagnazzo, Celeste

AU - Foresto, Manuela

AU - Longo, Virginia

AU - Berchialla, Paola

AU - Solinas, Gianfranca

AU - Calori, Adele

AU - Grasso, Bruna

AU - Volpone, Chiara

AU - Bertola, Gisella

AU - Parola, Gisella

AU - Tealdi, Giancarla

AU - Giuliano, Piero Luigi

AU - Ballari, Anna Maria

AU - Aglietta, Massimo

AU - Montemurro, Filippo

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.

AB - Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.

KW - adjuvant chemotherapy

KW - breast cancer

KW - chemotherapy-related side effects

KW - common toxicity criteria for adverse events

KW - duration

KW - patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=85050930703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050930703&partnerID=8YFLogxK

U2 - 10.1002/cam4.1687

DO - 10.1002/cam4.1687

M3 - Article

AN - SCOPUS:85050930703

VL - 7

SP - 4339

EP - 4344

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 9

ER -